Tennessee Senate Bill SB2323

Tennessee 2025-2026 Regular Session

• Introduced: 2/2/26
• Chaptered: 5/5/26
• Passed: 5/5/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 39, Chapter 17, Part 4, relative to drugs.

Impact

The passing of SB2323 will likely have a significant impact on how pharmacies operate, particularly in their obligations to comply with the electronic sales tracking requirements. Pharmacies will be required to maintain equipment for this tracking system and to submit sales data in real-time. The act is designed to reduce the illegal sale of methamphetamine precursors and contribute to public safety concerns regarding drug abuse. As a part of the law, those placed on a methamphetamine registry will be flagged in the system, preventing them from purchasing certain over-the-counter medications.

Summary

Senate Bill 2323 aims to amend the Tennessee Code Annotated, specifically focusing on regulations surrounding the sale of drugs containing pseudoephedrine and ephedrine, both of which are known precursors for methamphetamine production. The bill introduces provisions for an electronic sales tracking system to monitor the purchase of these substances, requiring pharmacies to report sales data electronically to prevent illegal sales. This system will enhance the state's capability to control and monitor the distribution of such drugs more effectively.

Contention

Some points of contention surrounding SB2323 may arise from discussions on the balance between legal sales of medications and strict monitoring of such sales. Pharmacists may express concerns about the burden of compliance with the electronic system and the implications for their practice in terms of patient counseling and legitimate sales. Additionally, the bill could trigger debate about privacy concerns, as it involves tracking personal purchasing data of individuals buying products containing pseudoephedrine and ephedrine. From a legislative perspective, balancing access to medications with public safety through effective tracking remains a major contentious issue.